Galmed Pharmaceuticals Ltd. (GLMD)
Stock Price:
$3.21 USD
-0.11 (-3.31%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
After-hours: $3.37 +0.16 (4.98%) Oct 26, 5:10 PM
Key Info
| Market Cap |
67.77M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-20.46M |
| Shares Out |
21.11M |
| EPS (ttm) |
-1.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$3.21 |
| Previous Close |
$3.32 |
| Change ($) |
-0.11 |
| Change (%) |
-3.31% |
| Day's Open |
3.30 |
| Day's Range |
3.16 - 3.30 |
| Day's Volume |
37,469 |
| 52-Week Range |
3.02 - 7.38 |
More Stats
| Market Cap |
67.77M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
21.11M |
| Float |
15.65M |
| EPS (basic) |
-0.97 |
| EPS (diluted) |
-1.16 |
| FCF / Share |
-0.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
47,231 |
| Short Ratio |
0.54 |
| Short % of Float |
0.30% |
| Beta |
2.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.17 |
| Revenue |
n/a |
| Operating Income |
-22.38M |
| Net Income |
-20.46M |
| Free Cash Flow |
-14.95M |
| Net Cash |
75.25M |
| Net Cash / Share |
3.56 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-21.60% |
| ROE |
-34.53% |
| ROIC |
-34.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.60*
(510.59% upside)
Low
10.0
Current: $3.21
High
29.0
Target: 19.60
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 2.04 | 1.09 | 0.47 | - | - | - | - |
| Revenue Growth | - | 87.83% | 132.33% | - | - | - | - | - |
| Gross Profit | - | 2.04 | 1.09 | 0.47 | - | - | - | - |
| Operating Income | -22.38 | -10.72 | -12.36 | -16.88 | -10.88 | -9.14 | -14.57 | -3.14 |
| Net Income | -20.46 | -9.86 | -12.30 | -16.95 | -10.62 | -9.10 | -17.49 | -3.15 |
| Shares Outstanding | 21.11 | 18.14 | 12.49 | 11.37 | 11.10 | 10.32 | 5.07 | 4.96 |
| Earnings Per Share | -0.97 | -0.54 | -0.98 | -1.49 | -0.96 | -0.88 | -3.45 | -0.63 |
| Operating Cash Flow | -14.94 | -9.02 | -12.07 | -12.13 | -8.47 | -9.24 | -2.52 | -3.08 |
| Capital Expenditures | -0.01 | -0.09 | -0.01 | - | -0.16 | -0.77 | - | -0.03 |
| Free Cash Flow | -14.95 | -9.11 | -12.08 | -12.13 | -8.63 | -10.01 | -2.52 | -3.11 |
| Cash & Equivalents | 75.60 | 90.19 | 19.00 | 15.45 | 23.00 | 31.99 | 0.14 | 0.72 |
| Total Debt | 0.35 | - | - | - | - | - | - | 1.84 |
| Net Cash / Debt | 75.25 | 90.19 | 19.00 | 15.45 | 23.00 | 31.99 | 0.14 | -1.13 |
| Assets | 77.14 | 90.60 | 19.64 | 16.45 | 24.26 | 32.93 | 0.17 | 0.76 |
| Liabilities | 7.29 | 2.71 | 3.85 | 5.38 | 2.72 | 1.52 | 2.12 | 2.74 |
| Book Value | 69.85 | 87.89 | 15.80 | 11.08 | 21.55 | 31.41 | -1.95 | -1.98 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Galmed Pharmaceuticals Ltd. |
| Country |
Israel |
| Employees |
17 |
| CEO |
Allen Baharaff |
Stock Information
| Ticker Symbol |
GLMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GLMD |
| IPO Date |
March 13, 2014 |
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Company to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of non-alcoholic steatohepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.